Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Biologic Stories

2013-10-15 00:20:45

Copenhagen biopharmaceutical manufacturing facility expanded to support growing customer demand for clinical and commercial production COPENHAGEN, Denmark and SEATTLE, Oct. 15, 2013 /PRNewswire/ -- CMC Biologics has received renewal of its manufacturing and importation authorization (MIA) for Good Manufacturing Practice (cGMP) production of clinical and commercial manufacturing from the Danish Medicines Agency (DKMA), a division of the Danish Health and Medicines Authority. The DKMA...

2013-10-14 08:24:14

Adds Biologics to its Pet Therapeutics Platform KANSAS CITY, Kan. and BOSTON, Oct. 14, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets (pet therapeutics), today announced that it has entered into a merger agreement providing for the strategic acquisition of Vet Therapeutics, Inc., a San Diego-based company with a proprietary antibody-based biologics...

2013-10-12 23:02:01

RnRMarketResearch.com adds Latest Report on “Biological and Biosimilars Drug Market in Poland 2013” to its store. The report provides Biologic and biosimilars drug market in Poland 2013, Development forecasts for 2013-2015 is a long-awaited business information tool. Dallas, TX (PRWEB) October 12, 2013 Examine the future of biologics in the Polish pharma market. Report surveys biologic and biosimilar drugs, epidemiology and growth potential 2013- 2015. In Poland, as in many parts of...

2013-10-10 23:23:12

Therapy Class Overview: Rituximab biosimilar is the new market research report added to ReportsnReports.com store. Dallas, Texas (PRWEB) October 10, 2013 Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade, which is approved for RA, Crohn's disease and several other conditions and had $2 billion in sales in Europe last year. This...

2013-10-10 16:27:10

International Plasma Awareness Week, October 13-20 ANNAPOLIS, Md., Oct. 10, 2013 /PRNewswire/ -- The Plasma Protein Therapeutics Association (PPTA) and its member companies, the major collectors of human plasma and manufacturers of plasma protein therapies will hold their annual PPTA Business Forum in Denver on October 13. The meeting coincides with a kickoff celebration for International Plasma Awareness Week (IPAW), October 13-20, a new global awareness event designed to: -- Raise...

2013-10-10 16:27:08

International Plasma Awareness Week, October 13-20 ANNAPOLIS, Md., Oct. 10, 2013 /PRNewswire/ -- The Plasma Protein Therapeutics Association (PPTA) and its member companies are sponsoring International Plasma Awareness Week, October 13-20, designed to: -- Raise global awareness about source plasma collection -- Recognize the contributions of plasma donors in saving and improving lives -- Increase understanding about lifesaving plasma protein therapies and rare...

2013-10-10 12:28:39

CARLSBAD, Calif., Oct. 10, 2013 /PRNewswire/ -- Advanced Biologics, developers and marketers of OsteoAMP® Allogeneic Morphogenetic Protein, announced today that it will be presenting new data and also showcasing a new graft delivery device at two of the larger, global orthopaedic meetings this week; the North American Spine Society (NASS) annual meeting in New Orleans, LA, and the Combined Meeting of Orthopaedic Research Societies (CORS) meeting in Venice, Italy. An abstract...

2013-10-09 08:27:19

SOUTH SAN FRANCISCO, Calif., Oct. 9, 2013 /PRNewswire/ -- Catalyst Biosciences, Inc., focused on discovering and developing novel biopharmaceutical products based on engineered human proteases, and Isu Abxis, an established biologics manufacturing and development company based in Seoul Korea, announced today the companies have formed a strategic collaboration to develop Catalyst's next-generation Factor IX development candidate FIX-NG (CB 2679d) for the prevention and treatment of...

2013-10-07 16:25:21

NEWARK, Del., Oct. 7, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO), a biotechnology company focused on commercializing its proprietary transformative recombinant platform technology for development and production of biologics using transient gene expression in unmodified green plants, today confirmed, as required by Section 610(b) of the NYSE MKT Company Guide, the receipt of an audit opinion for its year ended June 30, 2013, containing a going concern qualification. This...

2013-10-03 00:20:13

THOUSAND OAKS, Calif. and GAITHERSBURG, Md., Oct. 3, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca (AZN), with its biologics research and development arm MedImmune, today announced the upcoming presentation of several key studies evaluating brodalumab, a human monoclonal antibody targeting the interleukin-17 (IL-17) receptor, for the treatment of moderate to severe psoriasis at the 22(nd) Congress of the European Academy of Dermatology and Venereology (EADV) in Istanbul, Oct....